CD19 and B-cell chronic lymphocytic leukemia: This is also true for the recently published primary analysis of the TRANSCEND CLL 004 study including 117 patients with relapsed or refractory CLL, which showed efficacy of CD19 CAR T cells only in a subset of patients46.